EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Dupilumab: Mechanism of action, clinical, and translational science

Marc R McCann iD, Matthew P Kosloski iD, Christine Xu, John D Davis iD, Mohamed A Kamal

Clinical and Translational Science · 2024-08 · 17 (8)

DOI: 10.1111/cts.13899 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 30.07.2024. Verfasst von Marc R McCann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interleukin-4 Receptor alpha Subunit, Dermatitis, Atopic, Interleukin-13. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allergic disease prevalence has increased globally with the subset of type 2 inflammatory diseases playing a substantial role. Type 2 inflammatory diseases may differ in clinical presentation, but they exhibit shared pathophysiology that is targeted by the unique pharmacology of dupilumab. Dupilumab binds to the interleukin (IL)‐4 receptor alpha subunit (IL‐4Rα) that blocks IL‐4 and IL‐13 signaling, two key drivers of type 2 inflammation. Herein, we review the mechanism of action and pharmacology of dupilumab, and the clinical evidence that led to the regulatory approvals of dupilumab for the treatment of numerous type 2 inflammatory diseases: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedInterleukin-4 Receptor alpha SubunitDermatitis, AtopicInterleukin-13Translational Research, BiomedicalHumansInterleukin-4AsthmaEosinophilic EsophagitisSignal TransductionNasal PolypsPrurigoTranslational Science, BiomedicalSinusitis

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedInterleukin-4 Receptor alpha SubunitInterleukin-13Interleukin-4IL4R protein, humanIL4 protein, human

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • Sanofi, Bridgewater, New Jersey, USA.

ORCID-Profile: Marc R McCann, Matthew P Kosloski, John D Davis

Zitieren

APA

McCann, M. R., Kosloski, M. P., Xu, C., Davis, J. D., & Kamal, M. A. (2024). Dupilumab: Mechanism of action, clinical, and translational science. Clinical and Translational Science, 17(8). https://doi.org/10.1111/cts.13899

Vancouver

McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA. Dupilumab: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 2024;17(8). doi:10.1111/cts.13899

BibTeX
@article{McCann2024,
  author = {McCann, Marc R and Kosloski, Matthew P and Xu, Christine and Davis, John D and Kamal, Mohamed A},
  title = {Dupilumab: Mechanism of action, clinical, and translational science},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {8},
  doi = {10.1111/cts.13899}
}
Kostenlos starten →